- Published at
- by manilatimes.net
mixed
mixed
News for Alpha Healthcare Acquisition Co (ALPAU)
- Published at
- by seekingalpha.com
mixedmixed- Published at
- by seekingalpha.com
positivepositiveHumacyte: Opportunity In Wound Healing - A Buy Before Price Gets Too High (NASDAQ:HUMA)
Humacyte's stock price has recently been on an impressive bull run. Read why I could see HUMA achieving a billion-dollar valuation within the next 12 months.- Published at
- by globenewswire.com
mixedmixedHumacyte First Quarter 2024 Financial Results and Business Update
-Biologics License Application (BLA) for HAV™ Accepted by FDA- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August...- Published at
- by globenewswire.com
neutralneutralHumacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
-Biologics License Application (BLA) for HAV™ Accepted by FDA on February 8, 2024- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA...- Published at
- by seekingalpha.com
positivepositiveSPAC Alpha Healthcare III shareholders approve Carmell merger (NASDAQ:ALPA)
Alpha Healthcare Acquisition Corp. III (ALPA) shareholders have approved a proposed merger with allogeneic biomaterials developer Carmell Therapeutics. Read more here.- Published at
- by marketscreener.com
positivepositiveAlpha Healthcare Acquisition III : Material Agreement - Form 8-K
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...- Published at
- by marketscreener.com
mixedmixedCarmell Therapeutics Merger With Alpha Healthcare Acquisition Corp III (Nasdaq: ALPA) July 6, 2023 - Form 8-K
Carmell Therapeutics Merger With Alpha Healthcare Acquisition Corp III July 6, 2023 PRESENTERS Rajiv Shukla Chairman & CEO,...- Published at
- by globenewswire.com
mixedmixedHumacyte First Quarter 2023 Financial Results and Business Update
- Human Acellular Vessel™ (HAV™) granted second RMAT designation by the FDA, for Vascular Trauma - - Completion of enrollment in Phase 3...- Published at
- by globenewswire.com
mixedmixedHumacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update
-- Enrollment Nearing Completion in Human Acellular Vessel™ (HAV™) Phase 2/3 Trial in Vascular Trauma and Phase 3 Trial in Arteriovenous (AV) Access in...